Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects
This article was originally published in Scrip
Working hard to re-boot its cancer strategy, Sanofi SA of France has entered its latest multi-year collaboration in the field, this time with German biotech BioNTech AG to discover and develop up to five immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).
You may also be interested in...
BioNTech gets an €80m boost to its reserves as Sanofi takes equity stake as partners extend 2015 deal and advance an mRNA-based cancer immunotherapy into clinic against multiple solid tumors
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.